Alternative splicing impairs soluble guanylyl cyclase function in aortic aneurysm

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 11, 2014, Pages H1565-H1575

  Martin, Emil ^a   Golunski, Eva ^a   Laing, Susan T ^a   Estrera, Anthony L ^a   Sharina, Iraida G ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Alternative splicing; Aorta; Nitric oxide; Soluble guanylyl cyclase

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; SOLUBLE GUANYLYL CYCLASE ALPHA 1; SOLUBLE GUANYLYL CYCLASE BETA 1; UNCLASSIFIED DRUG; CELL RECEPTOR; SOLUBLE GUANYLYL CYCLASE;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ANEURYSM SURGERY; AORTA; AORTA ANEURYSM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NUCLEOTIDE SEQUENCE; OXIDATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; VASCULAR DISEASE; VASCULAR TISSUE; VERY ELDERLY; ANIMAL; COS 1 CELL LINE; ENZYMOLOGY; GENETICS; GENOTYPE; MIDDLE AGED; MOLECULAR CLONING; PERSONALIZED MEDICINE; PHYSIOLOGY; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANIMALS; AORTIC ANEURYSM; CLONING, MOLECULAR; COS CELLS; CYCLIC GMP; FEMALE; GENOTYPE; GUANYLATE CYCLASE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PRECISION MEDICINE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84964698344     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00222.2014     Document Type: Article

References (50)

1. Baltrons MA, Garcia A. Nitric oxide-independent down-regulation of soluble guanylyl cyclase by bacterial endotoxin in astroglial cells. J Neurochem73: 2149–2157, 1999.
2. Bauersachs J, Bouloumie A, Mulsch A, Wiemer G, Fleming I, Busse R. Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc Res37: 772–779, 1998.
3. Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep60: 119–126, 2008.
4. Behrends S, Harteneck C, Schultz G, Koesling D. A variant of the alpha 2 subunit of soluble guanylyl cyclase contains an insert homologous to a region within adenylyl cyclases and functions as a dominant negative protein. J Biol Chem270: 21109–21113, 1995.
5. Behrends S, Steenpass A, Porst H, Scholz H. Expression of nitric oxide-sensitive guanylyl cyclase subunits in human corpus cavernosum. Biochem Pharmacol59: 713–717, 2000.
6. Booher AM, Isselbacher EM, Nienaber CA, Froehlich JB, Trimarchi S, Cooper JV, Demertzis S, Ramanath VS, Januzzi JL, Harris KM, O’Gara PT, Sundt TM 3rd, Pyeritz RE, Eagle KA, International Registry of Acute Aortic Dissection I. Ascending thoracic aorta dimension and outcomes in acute type B dissection (from the International Registry of Acute Aortic Dissection [IRAD]). Am J Cardiol107: 315–320, 2011.
7. Cabilla JP, Ronchetti SA, Nudler SI, Miler EA, Quinteros FA, Du-vilanski BH. Nitric oxide sensitive-guanylyl cyclase subunit expression changes during estrous cycle in anterior pituitary glands. Am J Physiol Endocrinol Metab296: E731–E737, 2009.
8. Chhajlani V, Frandberg PA, Ahlner J, Axelsson KL, Wikberg JE. Heterogeneity in human soluble guanylate cyclase due to alternative splicing. FEBS Lett290: 157–158, 1991.
9. Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, Behm DJ. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol3: 128, 2012.
10. Cote GJ, Zhu W, Thomas A, Martin E, Murad F, Sharina IG. Hydrogen peroxide alters splicing of soluble guanylyl cyclase and selectively modulates expression of splicing regulators in human cancer cells. PLos One7: e41099, 2012.
11. Dangel O, Mergia E, Karlisch K, Groneberg D, Koesling D, Friebe A. Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. J Thromb Haemost8: 1343–1352, 2010.
12. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation109: 27–32, 2004.
13. Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Ann Rev Biochem81: 533–559, 2012.
14. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cy-clase: discovery and therapeutic potential. Nature Rev Drug Disc5: 755–768, 2006.
15. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, Vita JA, Lerman A. The assessment of endothelial function: from research into clinical practice. Circulation126: 753–767, 2012.
16. Friedman KJ, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem274: 36193–36199, 1999.
17. Green KIL, Ri G. Aortic dissection. In: Cardiac Surgery in the Adult, edited by Cohn L. New York: McGraw-Hill, 2003, p. 1095–1122.
18. Ibarra C, Nedvetsky PI, Gerlach M, Riederer P, Schmidt HH. Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain. Brain Res907: 54–60, 2001.
19. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA308: 875–881, 2012.
20. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY, Waldman SA, Murad F. Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem261: 7236–7241, 1986.
21. Kloss S, Bouloumie A, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension35: 43–47, 2000.
22. Kloss S, Rodenbach D, Bordel R, Mulsch A. Human-antigen R (HuR) expression in hypertension: downregulation of the mRNA stabilizing protein HuR in genetic hypertension. Hypertension45: 1200–1206, 2005.
23. Kraehling JR, Busker M, Haase T, Haase N, Koglin M, Linnenbaum M, Behrends S. The amino-terminus of nitric oxide sensitive guanylyl cyclase alpha(1) does not affect dimerization but influences subcellular localization. PLos One6: e25772, 2011.
24. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA88: 4651–4655, 1991.
25. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem278: 22546–22554, 2003.
26. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, Kole R. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA97: 9591–9596, 2000.
27. Lamothe M, Chang FJ, Balashova N, Shirokov R, Beuve A. Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site? Biochemistry43: 3039–3048, 2004.
28. Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, Kwartler CS, Pannu H. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Ann Rev Genomics Human Genetics9: 283–302, 2008.
29. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med329: 2002–2012, 1993.
30. Noiri E, Lee E, Testa J, Quigley J, Colflesh D, Keese CR, Giaever I, Goligorsky MS. Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol Cell Physiol274: C236–C244, 1998.
31. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation97: 2494–2498, 1998.
32. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev87: 315–424, 2007.
33. Papapetropoulos A, Marczin N, Mora G, Milici A, Murad F, Catravas JD. Regulation of vascular smooth muscle soluble guanylate cyclase activity, mRNA, and protein levels by cAMP-elevating agents. Hypertension26: 696–704, 1995.
34. Pedraza CE, Baltrons MA, Heneka MT, Garcia A. Interleukin-1 beta and lipopolysaccharide decrease soluble guanylyl cyclase in brain cells: NO-independent destabilization of protein and NO-dependent decrease of mRNA. J Neuroimmunol144: 80–90, 2003.
35. Pyriochou A, Papapetropoulos A. Soluble guanylyl cyclase: more secrets revealed. Cell Signal17: 407–413, 2005.
36. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. CircRes85: 534–541, 1999.
37. Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Zhang WZ, Kaye DM. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation110: 3680–3686, 2004.
38. Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handbook Exp Pharmacol309–339, 2009.
39. Scott WS, Nakayama DK. Escherichia coli lipopolysaccharide down-regulates soluble guanylate cyclase in pulmonary artery smooth muscle. J Surg Res80: 309–314, 1998.
40. Seki J, Nishio M, Kato Y, Motoyama Y, Yoshida K. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis117: 97–106, 1995.
41. Sharina I, Sobolevsky M, Doursout MF, Gryko D, Martin E. Cobin-amides are novel coactivators of nitric oxide receptor that target soluble guanylyl cyclase catalytic domain. J Pharmacol Exp Ther340: 723–732, 2012.
42. Sharina IG, Cote GJ, Martin E, Doursout MF, Murad F. RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase. Nitric Oxide25: 265–274, 2011.
43. Sharina IG, Jelen F, Bogatenkova EP, Thomas A, Martin E, Murad F. Alpha1 soluble guanylyl cyclase (sGC) splice forms as potential regulators of human sGC activity. J Biol Chem283: 15104–15113, 2008.
44. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Hand Exp Pharmacol218: 279–313, 2013.
45. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guany-late cyclase stimulators. Handbook Exp Pharmacol277–308, 2009.
46. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation123: 2263–2273, 2011.
47. Takata M, Filippov G, Liu H, Ichinose F, Janssens S, Bloch DB, Bloch KD. Cytokines decrease sGC in pulmonary artery smooth muscle cells via NO-dependent and NO-independent mechanisms. Am J Physiol Lung Cell Mol Physiol280: L272–L278, 2001.
48. Verbeuren TJ, Jordaens FH, Van Hove CE, Van Hoydonck AE, Herman AG. Release and vascular activity of endothelium-derived relaxing factor in atherosclerotic rabbit aorta. Eur J Pharmacol191: 173–184, 1990.
49. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation105: 546–549, 2002.
50. Wilton SD, Fletcher S. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes. Curr Gene Ther11: 259–275, 2011.